UnileverIt named Nelson Peltz to its board on Tuesday as it engaged in discussions about strategy with American activist investor, who holds roughly 1.5% of the consumer goods company.

Unilever London, which is listed on the stock exchange, said that Peltz will be joining as a non executive director starting July. She will also join the compensation committee.

Peltz’s hedge funds Trian Fund Management, which represent 1.5% of British company Unilever, managed approximately 37.4M shares.

Peltz stated that they look forward to working with the Board and management to drive Unilever’s strategy, operations and sustainability and to increase shareholder value.

After months of news about his investment in Unilever (whose strategy came under fire this year following a brief pursuit), he was named to the position. GSK’sConsumer healthcare arm.

Nils Andersen, Unilever chair, stated that “we have had extensive and constructive conversations with him and his Trian team. We believe Nelson’s experiences in the global consumer good industry will be of benefit to Unilever.”

Unilever’s failure to pursue GSK’s consumer-health business at a cost of 50 billion pounds ($63 billion) had raised concerns about the plans of Chief Executive Officer Alan Jope.